Featured

Non-mutated tumor antigens in the spotlight for therapeutic targeting

Recent discoveries of unmutated aberrantly expressed tumor-specific antigens (aeTSAs) derived from non-coding regions and embryonic transcriptional programs has garnered attention as targets for immunotherapy. Apavaloaei et al. explored cell surface...

Read More

In the Spotlight...

Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade

Blanchard and Vina et al. investigated mechanisms by which anti-CTLA-4 mAbs modulate tumor-associated high endothelial venules (TA-HEVs), which are important for supporting lymphocyte entry into tumor...

Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy

To identify novel neoantigens, Cai et al. assembled an immunopeptidomics atlas from published tumor and normal tissue datasets. Non-canonical (non-coding; 15%) and canonical (85%) peptides exhibited s...

Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial

Saxena, Anker, Kodysh et al. demonstrated that the personalized long-peptide neoantigen vaccine PGV001, in combination with atezolizumab, was feasible, safe, and elicited durable neoantigen-specific T...

CD8+ T cell-derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells

Schiele, Japp, Stark et al. showed that up to half of tumor-specific CD8+ T cells in mice bearing CD40-expressing cancers were CD40L+. CD40L-/-CD8+ T cells transferred into RAG1-/- mice failed to reje...
See all for this week

Previous Digests

22nd CIMT Annual Meeting 2025

May 28, 2025

The ACIR team attended the 22nd CIMT Annual Meeting 2025 in Mainz, Germany. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. CIMT Lifetime achievement awardRolf Kiessling Keynote addressCornelis...

Hidden gems: cryptic antigens as novel therapeutic targets in pancreatic cancer

May 21, 2025

Pancreatic ductal adenocarcinoma (PDAC) has proven resistant to immunotherapy strategies, in part due to limited tumor mutational burden and T cell infiltration. Besides tumor-specific somatic mutations resulting in neoantigens, cancer cells can also translate genome regions outside of annotated...

Hydrogelation preserves whole tumor cells for vaccination

May 14, 2025

Whole tumor vaccines are appealing as immunotherapies, as they contain the complete range of potential tumor antigens. However, tumor cell inactivation methods often degrade important tumor cell structures and antigens, and the immunogenicity of whole tumor cell vaccines is...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Llambi

Gaelle Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Nathan Suek

Nathan Suek

Morgan Janes

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

 — Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials

Current Sponsors

Past Sponsors
Close Modal

Subscribe to our mailing list

GDPR Marketing Permissions

The Fritsch Foundation/ACIR.org will use the information you provide on this form to be in touch with you and to send you a weekly digest on cance immunotherapy. Click below to confirm that you want to receive the weekly digest by:

You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at contact@acir.org. We will treat your information with respect and will never share it with any third-parties. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.